logo

Moehs Group will participate in the Maghreb Pharma Expo, from October 1 to 3, 2019

Moehs Group will participate in the Maghreb Pharma Expo, from October 1 to 3, 2019

Leave a Comment / By

Maghreb Pharma is an international trade fair for the largest pharmaceutical industry in Africa, held between October 1 and 3, 2019.

It is an industry B2B platform that offers an opportunity to establish new alliances, meet local and international suppliers and keep up with the latest industry trends.

Data of interest:

Maghreb Pharma Expo receives more than 2400 professional visitors of pharmaceutical production for 3 days and more than 200 international exhibitors from 28 countries. More than 40 industrial seminars are organized during the show.

 

When?

From October 1 to 3, 2019

Where?

Center International des Conférences d’Algiers – CIC

Algiers, Algérie

STAND C5 EXHIBITOR

 

Do you want to contact?

Contact us for any information at: info@moehs.es

 

Leave a Comment

Your email address will not be published. Required fields are marked *

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.